These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12657252)

  • 1. Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors.
    Zhu G; Conner S; Zhou X; Shih C; Brooks HB; Considine E; Dempsey JA; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1231-5. PubMed ID: 12657252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
    Engler TA; Furness K; Malhotra S; Sanchez-Martinez C; Shih C; Xie W; Zhu G; Zhou X; Conner S; Faul MM; Sullivan KA; Kolis SP; Brooks HB; Patel B; Schultz RM; DeHahn TB; Kirmani K; Spencer CD; Watkins SA; Considine EL; Dempsey JA; Ogg CA; Stamm NB; Anderson BD; Campbell RM; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2261-7. PubMed ID: 12824014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors.
    Sanchez-Martinez C; Shih C; Faul MM; Zhu G; Paal M; Somoza C; Li T; Kumrich CA; Winneroski LL; Xun Z; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Considine E; Dempsey JA; Ogg CA; Campbell RM; Anderson BA; Wagner J
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3835-9. PubMed ID: 14552791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
    Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
    J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c]carbazoles: potent cyclin D1/CDK4 inhibitors.
    Faul MM; Engler TA; Sullivan KA; Grutsch JL; Clayton MT; Martinelli MJ; Pawlak JM; LeTourneau M; Coffey DS; Pedersen SW; Kolis SP; Furness K; Malhotra S; Al-awar RS; Ray JE
    J Org Chem; 2004 Apr; 69(9):2967-75. PubMed ID: 15104433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.
    Sanchez-Martinez C; Shih C; Zhu G; Li T; Brooks HB; Patel BK; Schultz RM; DeHahn TB; Spencer CD; Watkins SA; Ogg CA; Considine E; Dempsey JA; Zhang F
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3841-6. PubMed ID: 14552792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of novel inhibitors of cyclin-dependent kinases.
    Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
    Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1.
    Jeong HW; Kim MR; Son KH; Han MY; Ha JH; Garnier M; Meijer L; Kwon BM
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1819-22. PubMed ID: 10969976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
    Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
    J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.
    Al-awar RS; Ray JE; Hecker KA; Huang J; Waid PP; Shih C; Brooks HB; Spencer CD; Watkins SA; Patel BR; Stamm NB; Ogg CA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Grutsch JL; Joseph S
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3217-20. PubMed ID: 15149678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.
    Ryu CK; Kang HY; Lee SK; Nam KA; Hong CY; Ko WG; Lee BH
    Bioorg Med Chem Lett; 2000 Mar; 10(5):461-4. PubMed ID: 10743948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
    Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
    Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
    Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
    Kim KS; Kimball SD; Misra RN; Rawlins DB; Hunt JT; Xiao HY; Lu S; Qian L; Han WC; Shan W; Mitt T; Cai ZW; Poss MA; Zhu H; Sack JS; Tokarski JS; Chang CY; Pavletich N; Kamath A; Humphreys WG; Marathe P; Bursuker I; Kellar KA; Roongta U; Batorsky R; Mulheron JG; Bol D; Fairchild CR; Lee FY; Webster KR
    J Med Chem; 2002 Aug; 45(18):3905-27. PubMed ID: 12190313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K252a inhibits the phosphorylation of pRb without changing the levels of G1 cyclins and Cdk2 protein in human hepatoma cells.
    Nakayama T; Hashimoto Y; Kaneko Y; Kurokawa K
    Biochem Biophys Res Commun; 1996 Jul; 224(1):180-3. PubMed ID: 8694809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
    Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
    Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.